保守氧疗用于脓毒症机械通气成人:ICU-ROX试验事后分析
该研究为ICU-ROX试验的事后分析,纳入251例脓毒症机械通气患者,比较保守氧疗与常规氧疗。主要终点90天死亡率:保守氧疗组47/130(36.2%)vs 常规氧疗组35/120(29.2%),绝对差7个百分点(95%CI -4.6至18.6个百分点,P=0.24),脓毒症与非脓毒症交互作用P=0.35。保守氧疗组SpO2≥97%时间更短(23.5h vs 47h,绝对差23h,95%CI 8-38),FiO2 0.21时间更长(20.5h vs 0h,绝对差20h,95%CI 14-26)。次要结局无统计学显著差异,但点估计一致偏向常规氧疗。作者认为该事后分析把握度不足,不能排除保守氧疗的临床重要获益或危害。
要点
- 脓毒症机械通气患者90天死亡率:保守氧疗组36.2%(47/130)vs 常规氧疗组29.2%(35/120),绝对差7个百分点(95%CI -4.6至18.6),P=0.24。
- 保守氧疗组SpO2≥97%时间更短:23.5h(IQR 8-70)vs 47h(IQR 11-93),绝对差23h(95%CI 8-38)。
- 保守氧疗组FiO2 0.21时间更长:20.5h(IQR 1-79)vs 0h(IQR 0-10),绝对差20h(95%CI 14-26)。
- 次要结局无统计学显著差异,但点估计一致偏向常规氧疗。
- 作者认为该事后分析把握度不足,不能排除保守氧疗的临床重要获益或危害。
适用人群与场景
- 脓毒症合并机械通气的ICU成人患者,数据来自ICU-ROX试验中251例脓毒症患者的事后分析。
研究设计与关键结果
- 研究类型:ICU-ROX试验的事后分析,纳入251例脓毒症机械通气ICU患者,比较保守氧疗与常规氧疗。
- 主要终点90天死亡率:保守氧疗组47/130(36.2%)vs 常规氧疗组35/120(29.2%),绝对差7个百分点(95%CI -4.6至18.6个百分点,P=0.24),脓毒症与非脓毒症交互作用P=0.35。
- 保守氧疗组SpO2≥97%时间:23.5h(IQR 8-70)vs 常规氧疗组47h(IQR 11-93),绝对差23h(95%CI 8-38)。
- 保守氧疗组FiO2 0.21时间:20.5h(IQR 1-79)vs 常规氧疗组0h(IQR 0-10),绝对差20h(95%CI 14-26)。
- 次要结局(病因特异性死亡、ICU及住院时间、无呼吸机天数、无血管活性药天数、ICU内肾脏替代治疗比例)无统计学显著差异,但点估计一致偏向常规氧疗。
证据类型、等级与局限
- 证据类型:随机对照试验的事后分析。
- 局限:事后分析把握度不足,不能排除保守氧疗的临床重要获益或危害。
对床旁实践的改变
- 作者认为,保守氧疗对脓毒症机械通气患者90天死亡率的治疗效应点估计提示该干预可能存在临床重要危害,但事后分析把握度不足,不能排除临床重要获益或危害。
指南或共识出处
- ICU-ROX试验,澳大利亚和新西兰临床试验注册号ACTRN12615000957594。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Sepsis is a common reason for intensive care unit (ICU) admission and mortality in ICU patients. Despite increasing interest in treatment strategies limiting oxygen exposure in ICU patients, no trials have compared conservative vs. usual oxygen in patients with sepsis.
METHODS: We undertook a post hoc analysis of the 251 patients with sepsis enrolled in a trial that compared conservative oxygen therapy with usual oxygen therapy in 1000 mechanically ventilated ICU patients. The primary end point for the current analysis was 90-day mortality. Key secondary outcomes were cause-specific mortality, ICU and hospital length of stay, ventilator-free days, vasopressor-free days, and the proportion of patients receiving renal replacement therapy in the ICU.
RESULTS: Patients with sepsis allocated to conservative oxygen therapy spent less time in the ICU with an SpO2 ≥ 97% (23.5 h [interquartile range (IQR) 8-70] vs. 47 h [IQR 11-93], absolute difference, 23 h; 95% CI 8-38), and more time receiving an FiO2 of 0.21 than patients allocated to usual oxygen therapy (20.5 h [IQR 1-79] vs. 0 h [IQR 0-10], absolute difference, 20 h; 95% CI 14-26). At 90-days, 47 of 130 patients (36.2%) assigned to conservative oxygen and 35 of 120 patients (29.2%) assigned to usual oxygen had died (absolute difference, 7 percentage points; 95% CI - 4.6 to 18.6% points; P = 0.24; interaction P = 0.35 for sepsis vs. non-sepsis). There were no statistically significant differences between groups for secondary outcomes but point estimates of treatment effects consistently favored usual oxygen therapy.
CONCLUSIONS: Point estimates for the treatment effect of conservative oxygen therapy on 90-day mortality raise the possibility of clinically important harm with this intervention in patients with sepsis; however, our post hoc analysis was not powered to detect the effects suggested and our data do not exclude clinically important benefit or harm from conservative oxygen therapy in this patient group.
CLINICAL TRIALS REGISTRY: ICU-ROX Australian and New Zealand Clinical Trials Registry number ACTRN12615000957594.
参考来源
- Young P, Mackle D, Bellomo R, et al. Conservative oxygen therapy for mechanically ventilated adults with sepsis: a post hoc analysis of data from the intensive care unit randomized trial comparing two approaches to oxygen therapy (ICU-ROX). Intensive Care Med. 2019. PMID: 31748836. doi:10.1007/s00134-019-05857-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。